Entera Bio Ltd. (ENTX): Revenue
$42.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-32.1%
3-year compound annual growth
-35.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.0K | -76.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $181.0K | n/a | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $0 | -100.0% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $134.0K | -76.5% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $571.0K | +56.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $365.0K | n/a | 2022-03-08, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $42.0K | -76.8% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $50.0K | +257.1% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $22.0K | n/a |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $88.0K | -48.2% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $131.0K | -9.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $157.2K | +468.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $190.0K | -19.1% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $6.0K | -45.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $593.0K | -13.2% |
Compare ENTX, INMB, SNTI, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗